Notably, HRS cells consistently express PAR-2 at protein and transcriptional levels, suggesting this receptor is a potential target for NET-associated elastase, among other proteases (eg, FXa).5 While our report is the first to show elastase in cHL, evidence for elastase activity has been provided for both B-cell non-Hodgkin lymphomas, and T-cell lymphomas,38,39 corroborating the view that this enzyme is biologically active in hematopoietic tumors. This evidence concerns the gene F2RL1 and classic Hodgkin lymphoma.